Oncology biotech Monopar Therapeutics postpones $40 million IPO
Monopar Therapeutics, which is developing therapies for chemotherapy-induced mucositis and cancers, postponed its IPO on Wednesday, citing market conditions. It had filed to raise $40 million by offering 4.4 million shares at a price range of $8 to $10.
The Wilmette, IL-based company was founded in 2014 and had planned to list on the Nasdaq under the symbol MNPR. JonesTrading, Aegis Capital Corp., and Arcadia Securities were set to be the joint bookrunners on the deal.
Investment Disclosure: Renaissance IPO ETF (symbol: IPO) Renaissance International ETF (symbol: IPOS)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.